MOR107 (formerly LP2) is Lanthio Pharma’s lead product in clinical development. MOR107 is a stable and selective agonist of the angiotensin II type 2 (AT2) receptor
Apelins are the endogenous peptide ligands for the APJ receptor. Lanthio Pharma has discovered highly active and stable lanthi-apelins that differentially stimulate APJ-receptor–coupled intracellular pathways.
Natural galanin acts via three different receptor subtypes, GalR1, GalR2 and GalR3. Lanthio Pharma has discovered lanthi-galanins with enhanced subtype receptor specificities.